ACUTE MYELOID LEUKEMIA

The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein

Giulia Pianigiani, Francesca Rocchio, Sara Peruzzi, Vibeke Andresen, Barbara Bigerna, Daniele Sorcini, Michela Capurro, Bjørn Tore Gjertsen, Paolo Sportoletti, Mauro Di Ianni, Maria Paola Martelli, Lorenzo Brunetti, and Brunangelo Falini

INTRODUCTION

NPM1-mutated acute myeloid leukemia (AML) represents about one-third of all adult AML [1] and, due to its unique clinicopathological and genetic features [2], is recognized as a leukemia entity of the World Health Organization (WHO) Classification of myeloid neoplasms. Nucleophosmin (NPM1) is a multifunctional protein physiologically located in the nucleolus [2]. NPM1 mutations, the most common genetic lesion in AML, abrogate the ability of the protein to localize in the nucleolus and create a new nuclear export signal (NES) at the C-terminus, leading to enhanced nuclear export of mutant NPM1 and its aberrant accumulation in the cytoplasm of leukemic cells [1, 3, 4].

We demonstrated that the interaction between mutant NPM1 and the nuclear exporter Exportin-1 (XPO1) causes the aberrant cytoplasmic delocalization of mutant NPM1 and is responsible for the high expression of HOX genes in NPM1-mutated AML, since relocalization of the NPM1 mutant by XPO1 inhibitors causes early downregulation of HOX genes that is followed by cell differentiation and growth arrest [2, 5]. The rapid loss of HOX expression, despite XPO1 inhibition does not restore the physiologic localization of NPM1 to the nucleolus [5], strongly suggest that the interaction between XPO1 and mutant NPM1 (rather than its localization) is responsible for maintaining high HOX levels.

Another characteristic feature of NPM1-mutated AML is the absent/low expression of CD34 [6, 7] that yet remains poorly investigated. This feature, combined with the low HLA-DR [8], strong CD33 expression [9] and presence of abnormal PML bodies [10], is reminiscent of acute promyelocytic leukemia (APL) and have inspired APL-like treatment strategies (i.e., all-trans retinoic acid and arsenic trioxide) also in NPM1-mutated AML both preclinically [10] and in patients (NCT04689815, NCT03031249). Unlike HOX genes, CD34 expression seems to be independent from XPO1-mediated cytoplasmic dislocation of mutant NPM1. This is supported by the finding that in most NPM1-mutated AML patients, a small subset of early CD34+ hematopoietic precursors carrying NPM1 mutations/cytoplasmic NPM1 is usually present [11], suggesting a derivation from CD34+ hemopoietic stem cells, with the potential of multilineage differentiation. On the other hand, the observation that at least a percentage of NPM1-mutated AML may derive from CD34-negative hemopoietic stem cells, raises the question of a possible relationship between absent/low expression of CD34 and cytoplasmic dislocation of mutant NPM1 [12]. Clinically, CD34 expression in NPM1-mutated AML has been mostly associated with an adverse outcome [13].

To address this issue, we performed functional studies to assess whether the nuclear relocalization of the mutant NPM1 could result in the re-expression of CD34. Moreover, we searched for CD34+/NPM1 cytoplasmic precursors in the bone marrow (BM) biopsies of NPM1-AML patients at diagnosis and relapse, using a highly specific monoclonal antibody against mutant NPM1. The results of these studies are presented below.

RESULTS AND DISCUSSION

We first investigated whether cytoplasmic delocalization of mutant NPM1 could explain the absent/low expression of CD34 in NPM1-mutated AML. To this end, we assessed the effect of nuclear relocalization of mutant NPM1 on CD34 expression, using the selective XPO1 inhibitor selinexor, which blocks the nuclear export of XPO1 cargo proteins, including NPM1. We treated the NPM1-mutated OCI-AML3 cell line that does not express CD34 and two NPM1-mutated patient-derived xenograft (PDX) cells (PDX2 and PDX3) [5] that partially express CD34 with selinexor for 24 h. Immunofluorescence with a monoclonal antibody specific for mutant NPM1 showed that after 12 h of XPO1 inhibition, mutant NPM1 was completely relocated to the nucleus of AML cells (Fig. 1A, PDX2). Flow cytometry analysis performed at 12 and 24 h of treatment revealed that CD34 expression levels remained unchanged (Fig. 1B). CD34 expression was also studied by realtime PCR, confirming its low/absent expression in NPM1-mutated

1Section of Hematology, Department of Medicine and Surgery, Center for Hemato-Oncological Research (CREO), University of Perugia, Perugia, Italy. 2Research and Early Development, Dompé Farmaceutici S.p.A, Napoli, Italy. 3Centre for Cancer Biomarkers (CCBIO), Department of Clinical Science, University of Bergen, Bergen, Norway. 4Department of Medicine, Haematology Section, Haukeland University Hospital, Bergen, Norway. 5Department of Medicine and Sciences of Aging, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy. 6Department of Molecular and Clinical Sciences, Università Politecnica delle Marche, Ancona, Italy. 7These authors contributed equally: Giulia Pianigiani, Francesca Rocchio. 8These authors jointly supervised this work: Lorenzo Brunetti, Brunangelo Falini. 9Email: brunangelo.falini@unipg.it

Received: 3 March 2022 Revised: 3 May 2022 Accepted: 4 May 2022
Published online: 14 May 2022
AML cells and showing that levels did not change following XPO1 inhibition (not shown).

Selinexor does not specifically block the nucleo-cytoplasmic shuttling of mutant NPM1, abrogating also the nuclear export of all XPO1 cargo proteins. Therefore, we tested the effect of selective mutant NPM1 degradation on CD34 expression. For this purpose, we exploited two NPM1-mutated CRISPR-engineered cell lines (OCI-AML3 and IMS-M2) in which endogenous mutant NPM1 is fused to the FKBP36 degron tag and GFP (NPM1c-FKBPF36V, GFP, Supplementary Fig. S1A) [5]. This system enables fast and specific degradation of mutant NPM1 by addition of the small compound dTAG-13. We treated cells with either DMSO (control) or dTAG-13 for 72 h. As expected, dTAG-13 induced efficient degradation of mutant NPM1 in both CRISPR-engineered cell lines (Fig. 1C and Supplementary Fig. S1B). Immunoblotting confirmed the loss of fusion protein without changes in wild-type NPM1 (Supplementary Figs. S1D, E). Nonetheless, flow cytometry and overlaid histograms of CD34 expression showed that CD34 levels were not changed at all time points in both cell lines (Fig. 1D and Supplementary Fig. S1C). Altogether, these findings strongly suggest that CD34 expression is not dependent upon mutant NPM1 expression and/or localization.

We then investigated the expression of mutant NPM1 in CD34+ cells of BM biopsies from NPM1-mutated AML patients by double immunostaining. In a previous study [11], we had addressed this issue using a monoclonal antibody recognizing both the wild-type and mutant NPM1 protein. In this study, double immunostaining for CD34/NPM1 was carried out using the highly specific anti-NPM1 mutant antibody used for immunofluorescence, suitable for automated immunoperoxidase staining of paraffin-embedded BM biopsies fixed in formalin and decalcified in Osteodec (full details are given in the Supplementary Materials).

BM paraffin sections from 15 NPM1-mutated AML patients \( n = 10 \) at first diagnosis and \( n = 5 \) at relapse) were double stained for CD34 and mutant NPM1. Fourteen out of the 15 cases showed the presence of no or rare CD34/mutant NPM1 double-positive cells (Fig. 2A, B). One case of NPM1-mutated AML at relapse (FLT3-ITD positive) showed a higher percentage (up to 20%) of leukemic cells double stained for CD34 and cytoplasmic mutant NPM1 (Fig. 2C). Moreover, we performed immunofluorescence using the same anti-NPM1 mutant antibody in FACS-sorted CD34+ and CD34− leukemic cells from a 32-year-old female patient with high count NPM1-mutated AML (Supplementary Fig. S2A). Purified CD34+ and CD34− cells were spotted onto poly-L-lysine coated glass slides and immunostained with the specific anti-NPM1 mutant monoclonal antibody followed by anti-rabbit Alexa Fluor 488-conjugated secondary antibody (full details are provided in Supplementary Materials). Both CD34+ and CD34− leukemic cells showed cytoplasm-restricted positivity for the NPM1 mutant protein without nuclear staining (Fig. 2D).

Collectively, the above results strongly suggest that, unlike HOX genes [5], CD34 expression is not dependent on the expression or the delocalization of NPM1 mutant protein from the nucleus to the cytoplasm. In fact, neither nuclear relocalization nor selective degradation of mutant NPM1 induced changes in CD34 expression in our parental and CRISPR-engineered AML cell lines.
In conclusion, based on our functional and immunohistochemical studies, we hypothesize that most NPM1-mutated cells originate from an immature CD34+ hematopoietic cell [10], but the leukemic bulk population is detected at an abnormal differentiation stage in which HOX expression is still high whereas CD34 is already silenced. In this context, a minor “stem-like” population, which contains leukemia-initiating cells, and which may expand at relapse [11, 14], maintains both CD34 and high HOX levels. Indeed, as in the patient with high percentage of CD34+ cells described here, an increased CD34 expression at relapse has been reported in NPM1-mutated AML, particularly in association with FLT3-ITD [11, 15].

REFERENCES

1. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254–66.
2. Falini B, Brunetti L, Sportoletti P, Martelli MP. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood. 2020;136:1707–21.
3. Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukaemia. Blood. 2006;108:1999–2005.
4. Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009;23:1731–43.
5. Brunetti L, Gundy MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, et al. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell. 2018;34:499–512.
6. Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+) AML shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106:889–902.
7. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106:3747–54.
8. Oelschlaegel U, Mohr B, Schach M, Schakel U, Kroschinsky F, Illmer T, et al. HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia. Cytom B Clin Cytom. 2009;76:321–7.
9. De Propris MS, Raponi S, Diverio D, Milani ML, Meloni G, Falini B, et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica. 2011;96:1548–51.
10. Martelli MP, Gonfrendo I, Mezzasoma F, Milano F, Pierangeli S, Mulas F, et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood. 2015;125:3455–65.
11. Martelli MP, Pedtiroisi V, Theide C, Bonifacio E, Mezzasoma F, Cecchini D, et al. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood. 2010;116:3907–22.
12. Taussig DC, Vargaftig B, Miraki-Moud F, Griesinger E, Sharrock K, Luke T, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fraction. Blood. 2010;115:1976–84.
13. Dang H, Chen Y, Kamel-Reid S, Brandwein J, Chang H. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. Hum Pathol. 2013;44:2038–46.
14. Perriello VM, Gionfriddo I, Rossi R, Milano F, Mezzasoma F, Marra A, et al. CD123 is consistently expressed on NPM1-mutated AML cells. Cancers (Basel). 2021;13:496.
15. Angelini DF, Ottone T, Guererra G, Lavorgna S, Cittadini M, Bucissano F, et al. A leukemia-associated CD34/CD123/CD25/CD99+ immunophenotype identifies FLT3-mutated clones in acute myeloid leukemia. Clin Cancer Res. 2015;21:3977-85.

AUTHOR CONTRIBUTIONS
GP, FR and BF conceived the study. GP and FR performed in vitro experiments. BB performed IHC analysis. DS performed cell sorting. MDI provided patient samples and performed NGS analysis. SP, MC, VA, PS, MPM and BTG provided reagents and critical inputs. GP, FR, LB and BF analyzed the results and wrote the manuscript with the input from all the authors.

FUNDING
This work has been supported by the European Research Council (ERC-2016 ADG n. 740230 to BF), the Italian Association for Cancer research (AIRC; IG n. 23604 to BF and Start-Up 2019 n. 22895 to LB), the Norwegian Cancer Society (grants n. 303445 and 190175 to BTG) and the Trond Mohn Foundation recruitment program grant (to VA).

COMPETING INTERESTS
BF licensed a patent on NPM1 mutants (n. 102004901256449). BF and MPM declare honoraria/consultancy at scientific advisory board for Abbvie, Janssen, Novartis, AstraZeneca, Incyte. MPM also declares honoraria/consultancy at scientific advisory board for Abbvie, Amgen, Celgene, Janssen, Novartis, Pfizer, Jazz Pharmaceuticals. LB declares consultancy at scientific advisory boards for Abbvie and Amgen.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41375-022-01593-2.

Correspondence and requests for materials should be addressed to Brunangelo Falini.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.